Intense Neoadjuvant Chemotherapy with Cisplatin and Epirubicin for Advanced or Bulky Cervical and Vaginal Adenocarcinoma

• Published in: Gynecologic oncology Vol. 64; no. 3; pp. 431 - 435
• Main Authors: Zanetta, Gerardo, Lissoni, Andrea, Gabriele, Antonio, Landoni, Fabio, Colombo, Alessandro, Perego, Patrizia, Mangioni, Costantino
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 01.03.1997; Elsevier
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - surgery; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Chemotherapy, Adjuvant; Cisplatin - administration & dosage; Epirubicin - administration & dosage; Female; Follow-Up Studies; Humans; Hysterectomy; Medical sciences; Neoplasm Staging; Pharmacology. Drug treatments; Survival Rate; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - mortality; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - surgery; Vaginal Neoplasms - drug therapy; Vaginal Neoplasms - mortality; Vaginal Neoplasms - pathology; Vaginal Neoplasms - surgery; Adenocarcinoma; Antineoplastic agent; Human; Treatment efficiency; Vagina; Vaginal diseases; Malignant tumor; Uterine cervix; Cisplatin; Neoadjuvant treatment; Female genital diseases; Chemotherapy; Treatment; Advanced stage; Anthracyclins; Epirubicin; Preoperative; Uterine cervix diseases; Platinum II Complexes
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1006/gyno.1996.4561

Twenty-two consecutive patients with bulky or locally advanced cervical or vaginal adenocarcinoma were treated with a neoadjuvant chemotherapy regimen consisting of nine weekly courses of cisplatin (50 mg/m2) and three courses of epirubicin (70 mg/m2) at Weeks 1, 4, and 7, followed by radical hyster...